Search
Interferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalThe interferon is primarily produced by activated T lymphocytes and natural killer cells.
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated
ABT-510
go.drugbank.com/drugs/DB05434InvestigationalIt is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
TAK-754
go.drugbank.com/drugs/DB17850InvestigationalDeveloped by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]
Ferrous aspartate
go.drugbank.com/drugs/DB13220ExperimentalThe use of ferrous acetate over ferrous sulfate is currently undergoing an investigation by a clinical trial [L5464]. It is also used for dying of fabric or leather and as a wood preservative.
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalIt is being developed by CV Therapeutics, Inc.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalIt was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]
Luspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigationalLuspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...
Safflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnSafflower (Carthamus tinctorius L) is a herbaceous plant in the Asteraceae family. Extracted from the seeds of safflowers, safflower oil is a rich source of various saturated fatty acids, monounsaturated fatty acid (oleic acid) or essent...
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...